INCOG BioPharma Services, which debuted as a CDMO specializing in manufacturing sterile injectables in 2020, is expanding its production capacity with plans to add more than 100 new jobs.
The project, which was reported by the Indiana Business Journal to cost $125 million, will add a 100,000-square-foot manufacturing building to the company’s campus in Fishers, Indiana. Work is set to begin in August, the company said in a July 15 press release.
The expansion is designed to support INCOG’s production of autoinjectors, pens, wearable injectors and other products, plus add new capabilities for labeling and packaging.
“This supply chain integration is essential in accelerating a drug product to commercial launch, and even more important in today's constrained markets as the need for sterile injectable products is quickly growing to address challenging diseases and improve healthcare outcomes,” Cory Lewis, INCOG founder and chief executive, said in the release.
The Indiana Economic Development Corporation and the City of Fishers helped INCOG secure funding for the project.
INCOG announced the construction of its first facility on the site in 2022. The 90,000-square-foot production building was reported to cost $90 million. The company grew out of the demand for sterile injectable capacity triggered by the COVID-19 pandemic.